Sumatriptan Succinate

Specifications

103628-48-4CAS Number

600-463-4EC Number

butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamideIUPAC Name

C18H27N3O6SChemical Formula

413.5 g/molMolecular Weight

SUMATRIPTAN SUCCINATE; 103628-48-4; Sumavel DosePro; Alsuma; Onzetra Xsail; Imitrex Statdose; GR 43175C; Zembrace SymTouch; Sumatriptan Galpharm; Sumatriptan (as succinate); GR-43175C; NSC-760362; J8BDZ68989; CHEBI:64359; DTXSID60145966; Zecuity; Migraitan; Imigran subject; Migraleve ultra; Migraine Pack; Imigran 50; RefChem:56077; sumatriptan succinate tablet; DTXCID9068457; Sumatriptan Succinate, MENTHOLUM, BELLADONNA, IRIS VERSICOLOR, SANGUINARIA CANADENSIS; 1-(3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide succinate; Suminat; Sumatriptan succinate [USAN]; MFCD00902856; mitrex; Sumitrex; C18H27N3O6S; GR 43175; sumatriptan hydrogen succinate; Micralgin; Migratan; Sumatriptan (succinate); Migratriptan; Antibet; Arcoiran; Diletan; Imijekt; Novelian; Permicran; Sumadol; Sumatrin; Sumigrene; Migmax; Imitrex (TN); 1-{3-[2-(dimethylamino)ethyl]-1h-indol-5-yl}-n-methylmethanesulfonamide succinate; 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-, butanedioate (1:1); 3-[2-(DIMETHYLAMINO)ETHYL]-N-METHYL-1H-INDOLE-5-METHANESULFONAMIDE SUCCINATE; Zelrix; butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide; SMR000469158; Imigrane; UNII-J8BDZ68989; Sumatriptan SDI; 103628-48-4 (succinate); Zecutity (TN); Sumatriptan Succinate; GR 43175C; Sumatriptan succinate (GR 43175C); Ph Eur Sumatriptan Impurity Mixture; GR 43175X; Sumatriptan Test Mix for Impurity Identification Solution 2; Alsuma (TN); Sumave dosepro (TN); Sumatriptan succinate CRS; 3-(2-(Dimethylamino)ethyl)-N-methylindole-5-methanesulfonamide succinate (1:1); SCHEMBL41674; MLS001401405; MLS006011969; orb1227092; orb1310839; CHEMBL1201150; SCHEMBL29360288; Sumatriptan impurity mixture CRS; HY-B0121R; Sumatriptan succinate (JAN/USP); TO-303S; HMS2051H04; HMS2090G21; HMS2231K14; HMS3370G19; HMS3393H04; HMS3414A11; HMS3651E11; HMS3678A11; HMS3714G05; HMS3747O17; HMS3884K15; HMS5079K04; Pharmakon1600-01505372; SUMATRIPTAN SUCCINATE [MI]; SUMATRIPTAN SUCCINATE [JAN]; HY-B0121; Sumatriptan (succinate) (Standard); AC-751; EBC-03803; GW 102; HB1769; NSC760362; s8151; SN 308; SN-308; SUMATRIPTAN SUCCINATE [VANDF]; SUMATRIPTAN SUCCINATE [MART.]; 3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl-N-methylmethanesulfonamide Succinate; AKOS015900409; Sumatriptan for system suitability CRS; SUMATRIPTAN SUCCINATE [USP-RS]; SUMATRIPTAN SUCCINATE [WHO-DD]; AB07670; CCG-100994; CS-1884; FD27976; KS-1116; NC00244; NSC 760362; 1-[3-(2-DIMETHYLAMINOETHYL)-1H-INDOL-5-YL]-N-METHYL-METHANESULFONAMIDE SUCCINATE; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide,butanedioate(1:1); BS164422; DA-78115; Sumatriptan succinate - Bio-X trade mark; SY067033; SUMATRIPTAN SUCCINATE [ORANGE BOOK]; SUMATRIPTAN SUCCINATE [EP MONOGRAPH]; SUMATRIPTAN SUCCINATE [USP MONOGRAPH]; SW197624-3; D00676; EN300-122643; Sumatriptan succinate, >=98% (HPLC), solid; TREXIMET COMPONENT SUMATRIPTAN SUCCINATE; SR-01000763688; SR-01000763688-4; Q10374626; F0001-2411; Z1544404947; 3-(2-(Dimethylamino)ethyl)-N-methylindole-5-methanesulfonamide succinate; Sumatriptan succinate, European Pharmacopoeia (EP) Reference Standard; Sumatriptan succinate, United States Pharmacopeia (USP) Reference Standard; (3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide succinic acid; 1-(3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamidesuccinate; 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide;succinic acid; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide butanedioate; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; butanedioic acid; 3-[2-(Dimethylamino)ethyl]-N-methyl -1H-indole-5-methanesulfonamide succinate; N,N-dimethyl-2-{5-[(methylsulfamoyl)methyl]-1H-indol-3-yl}ethanaminium 3-carboxypropanoate; Sumatriptan for system suitability, European Pharmacopoeia (EP) Reference Standard; Butanedioic acid--1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide (1/1)Synonyms